BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25092113)

  • 1. DYRK1B variant linked to autosomal dominant metabolic syndrome.
    Hickmott J
    Clin Genet; 2015 Jan; 87(1):30-1. PubMed ID: 25092113
    [No Abstract]   [Full Text] [Related]  

  • 2. The metabolic syndrome and DYRK1B.
    Morita H; Komuro I
    N Engl J Med; 2014 Aug; 371(8):785. PubMed ID: 25140975
    [No Abstract]   [Full Text] [Related]  

  • 3. The metabolic syndrome and DYRK1B.
    He JL; Qiao GF; Li BY
    N Engl J Med; 2014 Aug; 371(8):785. PubMed ID: 25140974
    [No Abstract]   [Full Text] [Related]  

  • 4. The metabolic syndrome and DYRK1B.
    Mirshahi T; Murray MF; Carey DJ
    N Engl J Med; 2014 Aug; 371(8):784-5. PubMed ID: 25140973
    [No Abstract]   [Full Text] [Related]  

  • 5. The metabolic syndrome and DYRK1B.
    Keramati AR; Fathzadeh M; Mani A
    N Engl J Med; 2014 Aug; 371(8):785-6. PubMed ID: 25140972
    [No Abstract]   [Full Text] [Related]  

  • 6. DYRK1B haploinsufficiency in a family with metabolic syndrome and abnormal cognition.
    Orenstein N; Gofin Y; Shomron N; Ruhrman-Shahar N; Magal N; Hagari O; Azulay N; Bazak L; Goldberg Y; Basel-Salmon L
    Clin Genet; 2022 Feb; 101(2):265-266. PubMed ID: 34786696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain.
    Abu Jhaisha S; Widowati EW; Kii I; Sonamoto R; Knapp S; Papadopoulos C; Becker W
    Sci Rep; 2017 Jul; 7(1):6420. PubMed ID: 28743892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetics: Founder mutations identified in an inherited form of the metabolic syndrome.
    Holmes D
    Nat Rev Endocrinol; 2014 Jul; 10(7):377. PubMed ID: 24889900
    [No Abstract]   [Full Text] [Related]  

  • 9. A form of the metabolic syndrome associated with mutations in DYRK1B.
    Keramati AR; Fathzadeh M; Go GW; Singh R; Choi M; Faramarzi S; Mane S; Kasaei M; Sarajzadeh-Fard K; Hwa J; Kidd KK; Babaee Bigi MA; Malekzadeh R; Hosseinian A; Babaei M; Lifton RP; Mani A
    N Engl J Med; 2014 May; 370(20):1909-1919. PubMed ID: 24827035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of DYRK1B gene expression and its association with metabolic syndrome in a small cohort of Egyptians.
    Mohamed YA; Hassaneen HM; El-Dessouky MA; Safwat G; Hassan NA; Amr K
    Mol Biol Rep; 2021 Jul; 48(7):5497-5502. PubMed ID: 34291393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characterization of two DYRK1B variants causative of AOMS3.
    Detro-Dassen S; Sternberg A; Lehmann SM; Schwandt K; Düsterhöft S; Becker W
    Orphanet J Rare Dis; 2024 Jun; 19(1):233. PubMed ID: 38867326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative splicing variants of dual specificity tyrosine phosphorylated and regulated kinase 1B exhibit distinct patterns of expression and functional properties.
    Leder S; Czajkowska H; Maenz B; De Graaf K; Barthel A; Joost HG; Becker W
    Biochem J; 2003 Jun; 372(Pt 3):881-8. PubMed ID: 12633499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Novel DYRK1A mutations in 2 individuals with autosomal dominant mental retardation-7].
    Zou XM; Xiao H; He HL; Guang SQ; Peng J
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):804-806. PubMed ID: 31594070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyrk1B overexpression is associated with breast cancer growth and a poor prognosis.
    Chen Y; Wang S; He Z; Sun F; Huang Y; Ni Q; Wang H; Wang Y; Cheng C
    Hum Pathol; 2017 Aug; 66():48-58. PubMed ID: 28554575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.
    Kettle JG; Ballard P; Bardelle C; Cockerill M; Colclough N; Critchlow SE; Debreczeni J; Fairley G; Fillery S; Graham MA; Goodwin L; Guichard S; Hudson K; Ward RA; Whittaker D
    J Med Chem; 2015 Mar; 58(6):2834-44. PubMed ID: 25738750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway.
    Singh R; Dhanyamraju PK; Lauth M
    Oncotarget; 2017 Jan; 8(1):833-845. PubMed ID: 27903983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High diagnostic yield of clinically unidentifiable syndromic growth disorders by targeted exome sequencing.
    Kim YM; Lee YJ; Park JH; Lee HD; Cheon CK; Kim SY; Hwang JY; Jang JH; Yoo HW
    Clin Genet; 2017 Dec; 92(6):594-605. PubMed ID: 28425089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lrrk2 R1441 substitution and progressive supranuclear palsy.
    Ross OA; Whittle AJ; Cobb SA; Hulihan MM; Lincoln SJ; Toft M; Farrer MJ; Dickson DW
    Neuropathol Appl Neurobiol; 2006 Feb; 32(1):23-5. PubMed ID: 16409550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intragenic deletion in DYRK1A leads to mental retardation and primary microcephaly.
    van Bon BW; Hoischen A; Hehir-Kwa J; de Brouwer AP; Ruivenkamp C; Gijsbers AC; Marcelis CL; de Leeuw N; Veltman JA; Brunner HG; de Vries BB
    Clin Genet; 2011 Mar; 79(3):296-9. PubMed ID: 21294719
    [No Abstract]   [Full Text] [Related]  

  • 20. The serine, threonine, and/or tyrosine-specific protein kinases and protein phosphatases of prokaryotic organisms: a family portrait.
    Shi L; Potts M; Kennelly PJ
    FEMS Microbiol Rev; 1998 Oct; 22(4):229-53. PubMed ID: 9862122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.